Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Status:
Not yet recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
A single site, double-blinded, randomized controlled trial for postmenopausal women with
urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms.
Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or
daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.